SUVEN Life Sciences Ltd

News Release

Suven achieved a PAT of Rs.34.73 Crores for first Qtr of 2014-15, an increase of 16.68% compared to same quarter of previous year

HYDERABAD, INDIA (12 Aug' 2014) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter and year ended 30th Jun 2014. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 12th Aug 2014 at Hyderabad.

Financial Highlights for the 1st Quarter ended Jun' 2014:

Growth in revenue Rs 1426 Mn vs.Rs 1118 Mn - Up by 28%
Growth in PAT Rs 347 Mn vs. Rs 298 Mn - Up by 17%
Growth in EBIDTA Rs 590 Mn vs. Rs 462 Mn - Up by 28%

PAT during the quarter was reduced by Rs. 40.6 Mn, a charge of additional depreciation computed as per Schedule II of the Companies Act 2013 effective April 1, 2014, shown as exceptional item in Profit & Loss Account. Had the similar provisions of same quarter of previous years would have been followed, the PAT for this quarter would have been higher by Rs. 40.6 Mn.

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 89 Mn (6.28% on revenue) for the Qtr ended June' 2014.

For more information on Suven please visit our Web site at http://www.suven.com

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;